The aim of the study was to examine whether the circulating cell adhesion molecules, von Willebrand factor (vWf) and endothelin-1, are elevated in patients with essential hypertension with no other risk factors for atherosclerosis and thus may serve as a markers of endothelial dysfunction in uncomplicated hypertension. Furthermore, the effect of treatment with the ACE inhibitor, quinapril, on levels of endothelial dysfunction markers were studied. The levels of adhesion molecules (intercellular cell adhesion molecule-1 [ICAM-1], E-selectin, P-selectin), von Wilebrand factor (vWf) and endothelin-1 were measured in patients with hypertension without any other risk factors of atherosclerosis before and after treatment with quinapril (n = 22) and in normotensive controls (n = 22). Compared with normotensive subjects, the hypertensive patients had significantly higher levels of ICAM-1 (238 vs 208 ng/ml, P = 0.02), vWf (119 vs 105 IU/dl, P Ͻ 0.05) and endothelin-1 (5.76 vs 5.14 fmol/ml, P Ͻ 0.05). Three-month treatment of hyper-
Introduction
Hypertension is one of the main risk factors for cardiovascular diseases and accelerated development of atherosclerosis and its complications. The first tensive patients with quinapril led to a significant decrease in the levels of endothelin-1 (5.76 vs 5.28 fmol/ml, P Ͻ 0.01). We did not observe significant changes in the levels of adhesion molecules and vWf after ACE inhibitor treatment, although a trend toward a decrease was apparent with all these parameters. Patients with uncomplicated hypertension with no other risk factors of atherosclerosis had significantly elevated levels of ICAM-1, vWf, and endothelin-1. Our data suggest that these factors may serve as markers of endothelial damage even in uncomplicated hypertension. In hypertensive patients, treatment with the ACE inhibitor quinapril resulted in a significant decrease in endothelin-1 levels. These findings indicate a beneficial effect of ACE inhibitors on endothelial dysfunction in hypertensive patients. step in the development of atherosclerosis is impairment of the physiological function of vascular endothelium referred to as endothelial dysfunction. Cell adhesion molecules play an important role in this initial phase of development of atherosclerosis.
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Endothelial dysfunction in hypertensive individuals is characterised by impaired vasorelaxation mediated by endothelium (in the presence of a decreased activity of vasodilators, endotheliumderived relaxant factor/nitric oxide (EDRF/NO) in particular, and an increased activity of vasoconstrictor factors as endothelin), increased adhesion and Journal of Human Hypertension permeability of endothelial cells and structural changes of the vascular wall.
Endothelial dysfunction has been associated with increased expression of glycoprotein adhesion molecules of the selectin group 1 (E-selectin and Pselectin) and immunoglobulin group (intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). These surface molecules allow leukocytes to adhere to the endothelial surface and subsequently to migrate into the vessel wall. Subendothelial accumulation of inflammatory cells with subsequent formation of foam cells is the first step in the development of atherosclerosis. 2 Increased expression of cell adhesion molecules ICAM-1, VCAM-1 and E-selectin has been observed in human atherosclerotic plaques. 3, 4 Furthermore, the amount of soluble ICAM-1 and E-selectin released into the circulation has been demonstrated to directly correlate with the surface expression of ICAM-1 and E-selectin in a culture of endothelial cells. 5 Upregulation of adhesion molecule genes leads to the expression of membraneassociated adhesion molecules and release of their soluble forms. Based on these findings, we assume that circulating soluble adhesion molecules levels may act as markers of adhesion molecules expression in vivo. 6, 7 Increased plasma levels of E-selectin have been demonstrated in conditions associated with an increased risk for the development of atherosclerosis, eg, in type-2 diabetes mellitus 8 and in essential hypertension. 9 Patients with hypertension associated with other risk factors for atherosclerosis have been shown to exhibit elevated plasma levels of soluble ICAM-1, VCAM-1, E-selectin and von Willebrand factor (vWf). 10, 11 Elevated levels of soluble P-selectin were associated with increased risk of future myocardial infarction and cardiovascular death in apparently healthy women. 12 Increase plasma levels of P-selectin were also reported in patients with renovascular and malignant hypertension while the authors did not observe statistically significant changes in P-selectin levels in patients with primary hypertension. 13 The pathogenesis of arterial hypertension and its complications includes both mechanical factors (increase in blood pressure (BP), increased peripheral vascular resistance, and shear stress), and hormonal factors (renin-angiotensin-aldosterone (RAA) system, catecholamines, etc). Increased activity of the renin-angiotensin system is an important factor in the pathogenesis of arterial hypertension. Recently, it has been shown that intravenous angiotensin II infusion (at an initial dose of 1 ng/kg/min, increased each 30 min by 2 ng/kg/min to the final dose of 7 ng/kg/min) increases plasma ICAM-1 concentrations in healthy volunteers and subjects with essential hypertension, 14 thereby enhancing leukocyte adhesion and migration to the vascular wall. Selective blockade of the AT-1 receptor for angiotensin II then resulted in a decrease in serum ICAM-1 levels.
14 By contrast, a previous study described only slight, statistically non-significant increments (11%) of soluble ICAM-1, E-selectin and VCAM-1 levels in healthy volunteers during graded 4-h infusion of angiotensin II at doses up to 20 ng/kg/min (average dose 8 ng/kg/min). 15 The reason for this discrepancy is unclear.
Apart from the decrease in BP, one of the aims of antihypertensive therapy is the reversal of endothelial dysfunction. The studies described above indicate that angiotensin-converting enzyme (ACE) inhibitors, through their comprehensive action on the RAA system may improve impaired endothelial function in hypertensive subjects; one of the mechanisms of action of ACE inhibitors seems to be downregulation of cell adhesion molecules.
The present study focuses on whether plasma levels of adhesion molecules, vWf and endothelin-1 may serve as markers of endothelial dysfunction in hypertensive patients who have no other risk factor of atherosclerosis.
Aims of the study
Increased levels of soluble adhesion molecules have been reported in a number of studies in patients with overt atherosclerosis or with accumulation of risk factors of atherosclerosis [8] [9] [10] [11] and are thought to be markers of endothelial dysfunction in the early stages of atherosclerosis.
The aim of our study was to establish whether patients with uncomplicated essential hypertension with no other risk factors of atherosclerosis have increased levels of soluble adhesion molecules (Eselectin, P-selectin, and ICAM-1) and other potential markers of endothelial dysfunction (vWF, endothelin-1). A secondary aim was to assess the effect of antihypertensive therapy with the ACE inhibitor, quinapril, on levels of adhesion molecules and other endothelial dysfunction markers.
Subjects and methods

Subjects
In the period from March 1999 through January 2001 we examined at the Second Department of Internal and Cardiovascular Medicine, General University Hospital in Prague, Czech Republic, a total of 22 middle-aged men (35-66 years, mean age 50 ± 10 years) with mild essential hypertension (mean systolic BP 143 ± 18 mm Hg, mean diastolic BP 94 ± 8 mm Hg) with no other risk factors of atherosclerosis. They were either newly diagnosed patients, without any treatment, or hypertensive individuals examined after a 3-week discontinuation of antihypertensive therapy. A control group comprised 22 healthy age-matched men (34 -65 years, mean age 46 ± 7 years) with normal BP values (BP below 140/90 mm Hg, mean systolic BP 122 ± 11 mm Hg, diastolic BP 83 ± 6 mm Hg), without any risk factors of athero-sclerosis. The characteristics of the two groups are shown in Table 1 . Exclusion criteria included diabetes mellitus, marked hypercholesterolaemia, smoking, clinically overt form of atherosclerosis (coronary artery disease, stroke, peripheral vascular disease or carotid atherosclerosis), increased serum creatinine levels, and abnormal resting ECG. The patients had no serious concomitant disease, allergies, or recent acute infectious or inflammatory disease. The study was approved by the hospital's ethics committee and patients signed informed consent with their participation.
Methods
Baseline clinical assessment: BP values were measured using the current Guidelines for the Management of Hypertension by the WHO-ISH. The diagnosis of arterial hypertension was either established in patients by repeated BP measurements (three times) on two different visits, or the patients had been diagnosed to have hypertension previously and were already receiving treatment (n = 10), in which case they were examined after a 3-week discontinuation of therapy. Previous antihypertensive therapy included beta-blockers in six patients, calcium antagonists in two patients and a combination of beta-blockers and diuretics in two patients.
All subjects underwent a thorough physical examination, ECG, basic laboratory tests, and had a blood sample collected for the determination of markers of endothelial dysfunction. In patients with arterial hypertension, the examination was repeated after 3-month treatment with the ACE inhibitor quinapril at a dose of 5-40 mg daily with the mean dose of 13.2 ± 8.3 mg, depending on the BP levels. After 3 months of treatment with quinapril we observed a statistically significant decrease in BP-mean systolic BP decreased with ACE inhibitor therapy from 143 ± 15 mm Hg to 137 ± 15 mm Hg (P Ͻ 0.05) and mean diastolic BP from 94 ± 8 mm Hg to 88 ± 9 mm Hg (P Ͻ 0.01).
Laboratory methods: A venous blood sample was drawn in the morning (after an overnight fast) fol- 
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lowing a 20-min bedrest in the supine position. Blood samples were analysed using standard laboratory methods to determine basic laboratory parameters (ESR, electrolytes, creatinine, urea, lipoprotein spectrum, haemocoagulation parameters, CRP). The levels of soluble adhesion molecules E-selectin, P-selectin, and ICAM-1 were determined using commercial monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Abingdon, UK). The monoclonal antibodies used were specific for E-selectin, P-selectin and ICAM-1. Von Willebrand factor levels were measured in plasma by commercial ELISA kit using specific rabbit anti-human vWf antibodies (Asserachrom, Diagnostica Stago, France). Plasma levels of endothelin-1 were determined using radioimmunoassay commercial kit (DRG-Instruments GmbH, Marburg, Germany).
Statistical analysis
Statistical analysis was performed using JMP 3. 
Results
We did not find significant differences between hypertensives and controls in terms of age, body mass index, total cholesterol and glucose levels. Compared with controls, hypertensive patients had significantly higher systolic and diastolic BP values (Table 1) . Patients with uncomplicated essential hypertension had significantly higher levels of sICAM-1, vWf, and endothelin-1 as compared with controls ( Figure 1) . The groups did not differ significantly in the levels of E-selectin, P-selectin, fibrinogen, t-PA, and PAI. Values of the soluble adhesion molecules sICAM-1, sE-selectin, and P-selectin, vWF, other haemocoagulation parameters (fibrinogen, t-PA, PAI), endothelin-1 and nitric oxide are summarised in Table 2 .
Three-month treatment with the ACE inhibitor quinapril led to a significant decrease in the levels of endothelin-1 (P = 0.01) (see also Table 2 ).
ICAM-1 levels showed, during treatment, a statistically non-significant trend toward a decrease (11 ng/mL decrease, 95%CI (−1.2, 21.6)). No significant changes in the levels of adhesion molecules Eselectin (2.9 ng/mL decrease; 95%CI (−1.2; 7.2)) and P-selectin (2 ng/mL decrease; 95%CI (−12.5; 15.9), 
Data are expressed as means ± s.d., data for PAI values are expressed as median and interquartile range. P 1 values correspond with differences between hypertensive patients and controls, P 2 values with differences between hypertensive patients before and after ACEI therapy. P values Ͻ0.05 were considered as statistically significant.
vWf and haemocoagulation parameters were seen during quinapril therapy ( Table 2 ). The power calculation for observed changes in adhesion molecules and vWf was 50-55%. After quinapril therapy, the elevated levels of soluble ICAM-1, vWf and endothelin-1 in the hypertensive group decreased and no longer differed significantly from those of the control group.
Discussion
To our knowledge, all studies conducted to-date, demonstrating increases in the levels of soluble adhesion molecules and vWf included groups of patients with severe hypertension, overt atherosclerosis, other metabolic abnormalities or with a variety of risk factors of atherosclerosis. Our study was therefore designed to assess the effect of haemodynamic and humoral changes on impairing physiological endothelial function in patients with uncomplicated hypertension. No other conventional risk factors leading to endothelial dysfunction were present in our groups of hypertensive patients and healthy age-and sex-matched controls. Patients with mild arterial hypertension, free of other risk factors of atherosclerosis, were shown to have elevated serum levels of soluble adhesion molecule ICAM-1, endothelin-1 and vWf compared to controls. We thus believe the increased levels of ICAM-1, endothelin-1 and vWf directly reflect endothelial activation in the presence of an elevated blood pressure in the early stages of hypertension.
The exact mechanism by which arterial hypertension leads to the increase in levels of cell adhesion molecules and other endothelial factors is not fully understood. An important role is played by haemodynamic changes (increase in stroke volume and peripheral vascular resistance) as well as humoral changes affecting endothelial function. Some authors suggest a relationship between the increased activity of the renin-angiotensin system and development of atherosclerosis. Pastore et al 14 demonstrated increased expression and plasma levels of cell adhesion molecule ICAM-1 with intravenous angiotensin II infusion. Furthermore, angiotensin II have been shown to stimulate production of endothelin-1 16 and plasminogen-activator inhibitor-1 17 in vivo. Increased ICAM-1 levels have recently been reported in patients with coronary artery disease and were regarded as an independent risk factor of myocardial infarction in patients with coronary artery disease 18 and in healthy males. 19 Our finding of increased vWf levels in patients with uncomplicated mild essential hypertension extends the results of previous studies demonstrating elevated vWf levels in hypertensives with other risk factors of atherosclerosis 11 and in patients with overt atherosclerosis 20 even to the early stages of hypertension.
Unlike some other authors 9,11 we did not observe increased levels of E-selectin in our group of hypertensive subjects. All previous studies were conducted on groups of patients with severe hypertension, other risk factors of atherosclerosis (smoking, hyperlipidaemia, impaired glucose tolerance etc) or overt atherosclerosis. The increased levels of E-selectin thus may have reflected the effect of other risk factors damaging the endothelium. In our view, the different results reflect the different characteristics of groups of patients and controls.
We have also demonstrated significantly elevated plasma levels of endothelin-1 in hypertensive patients. This is consistent with data that emerged recently from studies performed on patients with essential hypertension without signs of damage to target organs 21 or on patients of African descent. 22 Given its marked vasoconstrictor, mitogenic, and inotropic properties, endothelin-1 might play a key role in the pathogenesis of increased peripheral vascular resistance and endothelial dysfunction in hypertensive individuals. Three-month treatment of mild arterial hypertension with the ACE inhibitor quinapril resulted in a significant decrease in endothelin-1 levels. The decrease in the plasma levels of the potent vasoconstrictor suggests a beneficial effect of ACE inhibitors on endothelial dysfunction in hypertensive patients and constitutes just another effect of the comprehensive action of ACE inhibitors.
By contrast, the levels of adhesion molecules and vWf were not significantly affected by quinapril; however, there was an apparent trend towards a decrease in all these parameters, and in ICAM-1 in Journal of Human Hypertension particular. The plasma levels of all of the target parameters did not differ significantly between hypertensive patients after ACE inhibitor treatment and the control group of healthy individuals. Failure to demonstrate significant decrease of E-selectin and ICAM-1 levels with ACE inhibitor therapy is in agreement with a previous study performed by Gasic et al 23 in borderline hypertensive patients with diabetes. On the contrary, Ferri et al 7 observed a significant 30-80% decrease of E-selectin and ICAM-1 levels in hypertensive patients treated with ACE inhibitors. The effect of ACE inhibitor therapy directly correlated with the dose of enalapril. Compared with our study Ferri et al 7 examined patients with more severe hypertension and the majority of patients also had other metabolic abnormalities. Thus the discrepancy between our results and data presented by Ferri et al 7 may reflect different groups of patients and a different type and dose of ACE inhibitor used. However the small number of patients limits the power of our study with regard to detecting changes in adhesion molecules with therapy. Thus we cannot exclude that failure to demonstrate a decrease in soluble adhesion molecules with therapy may be due to small numbers.
Conclusion
Patients with uncomplicated essential hypertension without other risk factors of atherosclerosis have been shown to have elevated plasma levels of intercellular cell adhesion molecule-1, vWf, and endothelin-1. Increased levels of ICAM-1, vWf, and endothelin-1 act as markers of endothelial dysfunction in patients with arterial hypertension. Treatment of hypertensive patients with the ACE inhibitor quinapril resulted in a significant decrease in elevated plasma levels of endothelin-1. ACE inhibitor therapy helps to normalise impaired endothelial functions in hypertensive subjects.
